Beta Bionics, a diabetes tech firm, receives mixed analyst ratings but sees insider buys, trading near $20. Beta Bionics, una empresa de tecnología de la diabetes, recibe calificaciones de analistas mixtos, pero ve compras de información privilegiada, trading cerca de $20.

Beta Bionics, a company developing diabetes solutions, has garnered mixed analyst ratings, including "outperform" and "neutral," with an average target price of $24.83 and a "Moderate Buy" consensus. Beta Bionics, una empresa que desarrolla soluciones para la diabetes, ha obtenido calificaciones de analistas mixtos, incluyendo "superación" y "neutral", con un precio objetivo promedio de $24,83 y un consenso de "Compra Moderada". The company's stock, which opened at $19.99, has seen significant share purchases by major shareholders and insiders. Las acciones de la compañía, que se abrió a $19.99, ha visto importantes compras de acciones por parte de los principales accionistas e informantes. Beta Bionics, founded in 2015, is based in Irvine, CA. Beta Bionics, fundada en 2015, tiene su sede en Irvine, CA.